Alliance for Pandemic Preparedness

July 21, 2020

Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020

Category:

Topic:

  • Havers et al. report a cross-sectional seroprevalence survey conducted on a convenience sample of residual sera collected from March 23 through May 12 for routine clinical testing in San Francisco (SF), Connecticut (CT), south Florida (SF), Louisiana (LA), Minneapolis-St Paul-St Cloud metro area (MN), Missouri (MS), New York City Metro Area (NYC), Philadelphia metro area (PA), Utah (UT), and western Washington state (WA) (n=16,025 individuals). Seropositivity ranged from 1% in SF (late April) to 7% in NYC (late March/early April).  
  • The estimated number of infections ranged from 6– to 24–times the number of reported cases. [EDITORIAL NOTE: Seropositivity in individuals undergoing routine clinical testing may not reflect seropositivity in the general population. A version of these findings was published as a pre-print article that was included in this Literature Report on June 29, 2020] 

Havers et al. (July 21, 2020). Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2020.4130